Western blotting analysis of CALU-3 and HCT116 cells TKI-resistant derivatives (ERL-R, GEF-R, VAN-R) following treatment with sorafenib.

<p>Western blotting analysis of C-RAF, B-RAF, MEK and MAPK activation following treatment with the indicated concentration of sorafenib of lung adenocarcinoma CALU-3 and colorectal cancer HCT116 cells TKI-resistant derivatives (ERL-R, GEF-R, VAN-R ). β-actin was included as a loading control.